Szijj, Peter A. http://orcid.org/0000-0002-2944-2676
Gray, Melissa A.
Ribi, Mikaela K. http://orcid.org/0000-0001-6816-8326
Bahou, Calise
Nogueira, João C. F. http://orcid.org/0000-0002-5992-5900
Bertozzi, Carolyn R. http://orcid.org/0000-0003-4482-2754
Chudasama, Vijay http://orcid.org/0000-0002-8876-3285
Funding for this research was provided by:
Wellcome Trust (175282, 214941/Z/18/Z)
Foundation for the National Institutes of Health (NIH R01 CA227942, NIH R01 CA227942, NIH R01 CA227942)
Leverhulme Trust (RPG-2020-010)
EC | Horizon 2020 Framework Programme (675007)
Article History
Received: 11 October 2022
Accepted: 21 June 2023
First Online: 24 July 2023
Competing interests
: M.A.G. and C.R.B. are inventors of a patent filed by Stanford University (international publication no. WO2018006034A1) titled ‘Conjugates for targeted cell-surface editing’ published on 4 January 2018 and licensed by Palleon Pharmaceuticals on 27 June 2017. C.R.B. is a cofounder and Scientific Advisory Board member of Palleon Pharmaceuticals, Enable Bioscience, Redwood Biosciences (a subsidiary of Catalent), InterVenn Biosciences, Lycia Therapeutics, Grace Science LLC and OliLux Biosciences. V.C. is a director of the spin-out ThioLogics and is an inventor of the patent filed by UCL Business PLC (European patent EP-2464654-B1) titled ‘Thiol protecting group’ published on 8 October 2014, and other patents derived thereof, as well as directly related patents in other jurisdictions that fall within the patent family. The remaining authors declare no competing interests.